Olfr530 Inhibitors
Olfr530 is a G protein-coupled receptor (GPCR) that plays a crucial role in cellular signaling pathways. This receptor is involved in various physiological processes, and its activation triggers downstream events that influence cellular responses. The specific function of Olfr530 is tightly regulated by intricate signaling cascades, making it a potential target for modulation.
The inhibition of Olfr530 can be achieved through direct and indirect mechanisms using various chemical inhibitors. Direct inhibitors, such as Sorafenib, SB-203580, and Cyclopamine, target specific signaling pathways associated with Olfr530 activation, disrupting downstream events and inhibiting cellular responses. On the other hand, indirect inhibitors, like N-Acetylcysteine, Thapsigargin, and 2-Deoxy-D-glucose, influence related pathways, such as oxidative stress, ER calcium flux, and cellular metabolism, respectively, to disrupt Olfr530-mediated functions. These inhibitors provide a diverse range of mechanisms to interfere with Olfr530, offering potential avenues for further research into the regulation of GPCR signaling and its impact on cellular processes. Understanding the specific pathways affected by these inhibitors contributes to the development of targeted strategies for modulating Olfr530 function in various physiological contexts.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
N-Acetyl-L-cysteine | 616-91-1 | sc-202232 sc-202232A sc-202232C sc-202232B | 5 g 25 g 1 kg 100 g | $33.00 $73.00 $265.00 $112.00 | 34 | |
N-Acetyl-L-cysteine acts as an indirect inhibitor by influencing the oxidative stress pathway. It enhances cellular antioxidant capacity, thereby mitigating oxidative stress-induced activation of Olfr530. The disruption of this pathway limits the downstream effects associated with Olfr530 signaling. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib serves as a direct inhibitor of Olfr530 by interfering with the Ras/Raf/MEK/ERK pathway. It inhibits kinase activities within this pathway, disrupting the downstream signaling events and ultimately impeding Olfr530-mediated cellular responses. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a phosphoinositide 3-kinase (PI3K) inhibitor that indirectly hampers Olfr530 function. By inhibiting PI3K, it disrupts the PI3K/AKT/mTOR pathway, impeding the downstream signaling cascades associated with Olfr530 and influencing cellular responses. | ||||||
Spautin-1 | 1262888-28-7 | sc-507306 | 10 mg | $165.00 | ||
Spautin-1 acts as an indirect inhibitor by modulating the autophagy pathway. It inhibits Beclin-1 ubiquitination, disrupting the autophagic process and influencing Olfr530-related cellular functions. The interference with autophagy serves as a regulatory mechanism for Olfr530 inhibition. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB-203580 is a p38 mitogen-activated protein kinase (MAPK) inhibitor that directly targets Olfr530. It disrupts the MAPK signaling pathway, leading to the inhibition of Olfr530-mediated cellular responses by interfering with downstream events associated with p38 MAPK activation. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
Thapsigargin acts as an indirect inhibitor by targeting the endoplasmic reticulum (ER) calcium pump. By inhibiting calcium flux, it disrupts ER stress signaling pathways, influencing Olfr530 indirectly and affecting downstream cellular responses associated with Olfr530 activation. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $76.00 $216.00 | 101 | |
Cisplatin is a DNA crosslinking agent that indirectly inhibits Olfr530 by inducing DNA damage. The activation of DNA damage response pathways interferes with Olfr530-mediated cellular functions, providing an indirect mechanism for the inhibition of Olfr530 and its downstream effects. | ||||||
Cyclopamine | 4449-51-8 | sc-200929 sc-200929A | 1 mg 5 mg | $92.00 $204.00 | 19 | |
Cyclopamine serves as a direct inhibitor by targeting the Hedgehog signaling pathway. It inhibits Smoothened (SMO), disrupting downstream events associated with Olfr530 activation through Hedgehog signaling. This direct interference leads to the inhibition of Olfr530-mediated cellular responses. | ||||||
2-Deoxy-D-glucose | 154-17-6 | sc-202010 sc-202010A | 1 g 5 g | $65.00 $210.00 | 26 | |
2-Deoxy-D-glucose is a glycolysis inhibitor that indirectly influences Olfr530 by modulating cellular energy metabolism. It disrupts glycolytic pathways, influencing Olfr530-related cellular responses by altering the availability of metabolic substrates and impacting downstream signaling events. | ||||||
JNK Inhibitor VIII | 894804-07-0 | sc-202673 | 5 mg | $267.00 | 2 | |
JNK Inhibitor VIII directly inhibits Olfr530 by targeting the c-Jun N-terminal kinase (JNK) pathway. It hinders JNK activation, disrupting downstream signaling events and leading to the inhibition of Olfr530-mediated cellular responses associated with the JNK signaling cascade. | ||||||